24×7 Online Assistance Email researchnnnn@gmail.com WhatsApp support Hours 24×7
DM · Super-Speciality (Medical)

Immunotherapy & Targeted Therapy and Palliative & Supportive Care Thesis Topics for DM Medical Oncology — 48+ titles

Updated November 2026 · reviewed against the current NMC / NBE curriculum

Hand-curated database of 48+ DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) dissertation titles, each ready with objectives, synopsis structure and protocol guidance. Unlock the objectives of any title instantly, or get the complete thesis plan — no signup.

48+DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) titles
24×7Instant objectives & thesis plans
100%Plagiarism-free, IEC-ready
Browse all 48 titles See a full thesis plan
Immunotherapy & Targeted Therapy and Palliative & Supportive Care thesis topics

DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) — Thesis Title List

48 titles · instant objectives
  1. 001

    Immune-related adverse events with checkpoint inhibitors across solid tumours: incidence, management and outcome

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  2. 002

    PD-L1 expression and its correlation with response to immunotherapy in non-small cell lung cancer and urothelial carcinoma

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  3. 003

    Efficacy and toxicity of tyrosine kinase inhibitors in metastatic renal cell carcinoma: a real-world analysis

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  4. 004

    Biosimilar versus innovator trastuzumab in HER2-positive breast cancer: response and safety

    Immunotherapy & Targeted Therapy Prospective comparative study Comparative Study
    Objective
  5. 005

    Clinical utility of next-generation sequencing in advanced solid tumours: actionable mutations and treatment impact

    Immunotherapy & Targeted Therapy Prospective observational study Descriptive Study
    Objective
  6. 006

    Symptom burden, quality of life and palliative care needs in patients with advanced cancer using ESAS and EORTC QLQ-C30

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  7. 007

    Prevalence and management of cancer pain and adequacy of analgesia using the WHO ladder in a tertiary oncology centre

    Palliative & Supportive Care Prospective observational study Cross-sectional Study
    Objective
  8. 008

    Chemotherapy-induced nausea and vomiting: adherence to antiemetic guidelines and control rates

    Palliative & Supportive Care Prospective audit Audit
    Objective
  9. 009

    Prevalence of malnutrition in cancer patients using PG-SGA and its impact on chemotherapy tolerance

    Palliative & Supportive Care Prospective observational study Cross-sectional Study
    Objective
  10. 010

    Depression, anxiety and financial toxicity in patients undergoing chemotherapy and their effect on treatment adherence

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  11. 011

    Chemotherapy-induced peripheral neuropathy with taxanes and platinum agents: incidence, risk factors and impact on quality of life

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  12. 012

    Adherence to oral anticancer agents and factors affecting it in patients with chronic myeloid leukaemia and breast cancer

    Palliative & Supportive Care Prospective observational study Cross-sectional Study
    Objective
  13. 013

    Response assessment with PET-CT versus contrast CT in lymphoma and solid tumours: concordance and impact on management

    Immunotherapy & Targeted Therapy Prospective observational study Diagnostic Study
    Objective
  14. 014

    Financial toxicity and out-of-pocket expenditure in cancer care at a public tertiary hospital

    Palliative & Supportive Care Cross-sectional study Cross-sectional Study
    Objective
  15. 015

    Anaemia in cancer patients on chemotherapy: prevalence, etiology and response to intravenous iron and erythropoietin

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  16. 016

    Low-dose versus standard-dose immune checkpoint inhibitors in advanced solid tumours: response, toxicity and cost

    Immunotherapy & Targeted Therapy Prospective comparative study Comparative Study
    Objective
  17. 017

    Baseline neutrophil-lymphocyte ratio as a predictor of response to immune checkpoint inhibitors

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  18. 018

    Incidence and predictors of hyperprogressive disease on immune checkpoint inhibitors

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  19. 019

    Tumour mutational burden on next-generation sequencing and outcome with immunotherapy in advanced solid tumours

    Immunotherapy & Targeted Therapy Prospective observational study Descriptive Study
    Objective
  20. 020

    Safety and outcome of immune checkpoint inhibitor rechallenge after immune-related adverse events

    Immunotherapy & Targeted Therapy Retrospective record-based study Descriptive Study
    Objective
  21. 021

    Real-world toxicity profile of antibody-drug conjugates in metastatic breast and gastric cancer

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  22. 022

    Tuberculosis reactivation in patients receiving immune checkpoint inhibitors in a high tuberculosis burden setting

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  23. 023

    Prevalence of drug interactions between oral tyrosine kinase inhibitors and acid-suppressive therapy

    Immunotherapy & Targeted Therapy Hospital-based cross-sectional study Cross-sectional Study
    Objective
  24. 024

    Uptake of immunotherapy through patient assistance programmes and factors affecting access

    Immunotherapy & Targeted Therapy Hospital-based cross-sectional study Cross-sectional Study
    Objective
  25. 025

    Early integrated palliative care versus standard oncology care on quality of life in advanced cancer

    Palliative & Supportive Care Prospective comparative study Comparative Study
    Objective
  26. 026

    Olanzapine 5 mg versus 10 mg for prevention of chemotherapy-induced nausea and vomiting

    Palliative & Supportive Care Prospective comparative study Comparative Study
    Objective
  27. 027

    Prevalence and correlates of cancer-related fatigue in patients receiving chemotherapy

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  28. 028

    Biosimilar pegfilgrastim as primary prophylaxis: incidence of febrile neutropenia and dose delays

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  29. 029

    Prevalence and management of opioid-induced constipation in patients with cancer pain

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  30. 030

    Incidence and severity of hand-foot syndrome with capecitabine and its effect on dose intensity

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  31. 031

    Caregiver burden and its determinants among caregivers of patients with advanced cancer

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  32. 032

    Awareness and preferences for advance care planning among patients with advanced cancer

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  33. 033

    Cardiovascular risk profile in breast cancer survivors after anthracycline and trastuzumab therapy

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  34. 034

    Incidence, clinical profile and outcome of immune checkpoint inhibitor-associated acute interstitial nephritis in patients with solid tumours

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  35. 035

    Incidence and timing of thyroiditis and hypophysitis in patients receiving PD-1 or PD-L1 inhibitors

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  36. 036

    Clinical, endoscopic and histological spectrum of immune checkpoint inhibitor-induced enterocolitis and response to steroids and infliximab

    Immunotherapy & Targeted Therapy Retrospective record-based study Descriptive Study
    Objective
  37. 037

    Homologous recombination deficiency status in high-grade serous ovarian cancer and progression-free survival on PARP inhibitor maintenance

    Immunotherapy & Targeted Therapy Prospective observational study Prospective Study
    Objective
  38. 038

    Effect of a supervised home-based exercise programme on cancer-related fatigue during adjuvant chemotherapy for breast cancer

    Palliative & Supportive Care Prospective comparative study Comparative Study
    Objective
  39. 039

    Prevalence of cancer cachexia by international consensus criteria and its association with chemotherapy tolerance in advanced gastrointestinal and lung cancer

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  40. 040

    Prevalence of sleep disturbance and its association with quality of life in patients receiving chemotherapy

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  41. 041

    Netupitant-palonosetron versus aprepitant-based triple antiemetic regimen for highly emetogenic chemotherapy-induced nausea and vomiting

    Palliative & Supportive Care Prospective comparative study Comparative Study
    Objective
  42. 042

    Afatinib versus gefitinib or erlotinib as first-line therapy in EGFR exon 19 deletion or L858R non-small cell lung cancer: progression-free survival and toxicity

    Immunotherapy & Targeted Therapy Prospective comparative study Comparative Study
    Objective
  43. 043

    Yield of RNA-based fusion testing after negative DNA-based next-generation sequencing in advanced solid tumours

    Immunotherapy & Targeted Therapy Prospective observational study Diagnostic Study
    Objective
  44. 044

    Prevalence of psychological distress on the NCCN Distress Thermometer at the first oncology visit and its associated problem domains

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  45. 045

    Patient and system delay from symptom onset to start of cancer treatment and the contribution of alternative medicine use

    Palliative & Supportive Care Hospital-based cross-sectional study Cross-sectional Study
    Objective
  46. 046

    Incidence and determinants of treatment abandonment and loss to follow-up among patients starting curative-intent chemotherapy

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  47. 047

    Tobacco cessation at six months after diagnosis and factors influencing quitting among patients with tobacco-related cancers

    Palliative & Supportive Care Prospective observational study Prospective Study
    Objective
  48. 048

    Prevalence of hepatitis B and C infection at cancer diagnosis and adherence to screening and antiviral prophylaxis before chemotherapy

    Palliative & Supportive Care Prospective audit Audit
    Objective

DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) thesis — frequently asked questions

How many DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) thesis topics are listed here?

48+ DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) thesis topics are listed on this page, organised by subsection of the Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) curriculum. Click "Get Objectives" on any title to unlock its aim, objectives and hypothesis instantly.

Do these Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) topics include the objective and synopsis?

Yes. "Get Objectives" unlocks the research question, aim, primary and secondary objectives, hypothesis and outcome measures. "Full Plan" unlocks the complete synopsis: introduction, review of literature search terms, methodology, sample-size calculation, statistical plan, ethics and timeline — ready to download as Word or PDF.

Are these topics suitable for DNB, DM and FCPS Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) candidates?

Yes — these Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) dissertation titles are aligned with NMC, NBE and DNB Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) curricula and are suitable for DM Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care), DNB Medical Oncology (Immunotherapy & Targeted Therapy and Palliative & Supportive Care) and FCPS candidates alike. We can also tailor a title to your institution's preferred study design.

Can you help with synopsis writing, protocol, data analysis and journal publication?

Yes. Beyond topic selection we provide end-to-end support: synopsis writing (NMC / NBE format), IEC / IRB-ready protocol drafting, data collection forms, statistical analysis (SPSS / R / STATA), full thesis writing, plagiarism check (Turnitin), and journal publication assistance (SCOPUS, UGC-CARE, PubMed-indexed).

How fast can I get the objective for a topic?

Instantly. After payment, the objectives open on screen in under a minute and the full plan in 1–3 minutes, 24×7. You can also click "WhatsApp" on any title to talk to our team.

WhatsApp